RxDoctor Payments Data

Jeffrey Wuhl, MD

Cardiovascular Disease · Wynnewood, PANPI 1740421346

Payments from drug & device makers

$16,532in general payments, 2019–2025

Across 185 payments — averaging $89.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$14K
  • Johnson & Johnson$771
  • Impulse Dynamics (USA) Inc.$536
  • Novo Nordisk$338
  • Amgen$325
  • Pfizer$147
  • plus $722 from 13 others

What the payments were for

  • Speaking & faculty fees$12,50076%
  • Food & beverage$4,01524%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,532 in reported general payments places this provider in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$416,229
Medicare patients
686
Services billed
2,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban173$169,959
XareltoRivaroxaban79$82,238
Repatha SureclickEvolocumab37$49,196
JardianceEmpagliflozin42$32,720
Nebivolol Hcl209$12,728
Rosuvastatin Calcium374$5,884
Atorvastatin Calcium231$2,603
Metoprolol Succinate133$2,123
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide37$2,072
Valsartan60$1,595
Dofetilide21$1,434
Amlodipine Besylate191$1,352
Lisinopril132$1,226
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide29$1,223
Chlorthalidone55$1,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$147$169,959173 claims
Johnson & JohnsonXarelto$771$82,23879 claims
Boehringer IngelheimJardiance$70$32,72042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →